Reply to Reader Comment on “Rituximab Lymphoma-Protocol May Be Superior for Inducing Remission in Pemphigus Vulgaris”

Abstract

Get full access to this article

View all access options for this article.

References

Muntyanu

Litvinov

Netchiporouk

. Rituximab lymphoma-protocol may be superior for inducing remission in pemphigus vulgaris. J Cutan Med Surg. 2020;24(5):523-524.doi:10.1177/1203475420926983

32401036

Kushner

CJ.

Wang

Tovanabutra

et al. Factors associated with complete remission after rituximab therapy for pemphigus. JAMA Dermatol. 2019;155(12):1404.doi:10.1001/jamadermatol.2019.3236 23 Oct 2019.31642878

Wang

H-H.

Liu

C-W.

Y-C.

Huang

Y-C

. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens. Acta Derm Venereol. 2015;95(8):928-932.doi:10.2340/00015555-2116

25881672

Ahmed

AR.

Shetty

. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015;14(4):323-331.doi:10.1016/j.autrev.2014.12.002

25499920

Kim

JH.

Kim

YH.

Kim

MR.

Kim

S-C

. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165(3):646-651.doi:10.1111/j.1365-2133.2011.10411.x

21574976

Amber

KT.

Hertl

. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2015;29(4):777-782.doi:10.1111/jdv.12678

25185723